CTLA4 and metastatic melanoma: The blocking of the physiological inhibitory function of CTLA-4 in T cells is the rationale for the employment of antagonistic anti-CTLA-4 mAbs as therapeutic tools to treat different solid tumors [15], mainly metastatic melanoma [16,17].